Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Usana Health Sciences (USNA) Shares Outstanding (2016 - 2026)

Usana Health Sciences has reported Shares Outstanding over the past 17 years, most recently at $18.5 million for Q2 2026.

  • Quarterly Shares Outstanding fell 1.75% to $18.5 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Apr 2026, down 1.75% year-over-year, with the annual reading at $18.3 million for FY2026, 4.11% down from the prior year.
  • Shares Outstanding was $18.5 million for Q2 2026 at Usana Health Sciences, up from $18.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $19.4 million in Q1 2022 and troughed at $18.3 million in Q2 2025.
  • The 5-year median for Shares Outstanding is $19.1 million (2023), against an average of $19.0 million.
  • Year-over-year, Shares Outstanding decreased 7.82% in 2022 and then rose 0.57% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $19.2 million in 2022, then fell by 0.4% to $19.1 million in 2023, then dropped by 0.35% to $19.1 million in 2024, then dropped by 4.15% to $18.3 million in 2025, then grew by 1.01% to $18.5 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Shares Outstanding are $18.5 million (Q2 2026), $18.3 million (Q1 2026), and $18.3 million (Q3 2025).